Clinical trials: Opioid Addiction
Heroin Dependence, Opioid-Related Disorders
Addiction Treatment in Russia: Oral vs. Naltrexone Implant
Heroin addiction is a growing problem in Russia; individuals who enter heroin addiction treatment often relapse. Therefore, effective heroin addiction treatments are necessary to prevent relapse.
- Trial name
- NCT00218426
- Testing
- naltrexone implant, oral naltrexone
- Where
- 2 sites in United States, Russia
- Volunteers
- 306 people
- Sponsor
- University of Pennsylvania
Opioid-use Disorder, Opioid-Related Disorders
Substance Use Treatment and Recovery Team (START)
Despite high prevalence, few hospitalized inpatients with opioid or alcohol use disorders (OAUDs) receive evidence-based treatments while in the hospital or get linked with appropriate follow-up care, leading to poor clinical…
- Conditions
- Opioid-use Disorder, Opioid-Related Disorders, Alcohol Use Disorder, Alcohol-Related Disorders
- Trial name
- START (NCT04314648)
- Testing
- Substance Use Treatment and Recovery Team (START)
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- RAND
Opiate Dependence
ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids
This was a Phase 2, multicenter, randomized, double-blind pilot study in opioid-using adults to assess the presence, duration, and degree of opiate blockade as well as the safety and tolerability of Medisorb® naltrexone…
- Trial name
- NCT01218984
- Testing
- Medisorb naltrexone 75 mg, Medisorb naltrexone 150 mg, Medisorb naltrexone 300 mg
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Opioid-use Disorder, Opioid Dependence
Remote Observed Dosing of Suboxone to Improve Clinical Practice
This is a 15-week, outpatient study of remote observed dosing to improve suboxone compliance in opiate dependent subjects.The main purpose of this study is to see if watching patients take their medication will improve treatment…
- Conditions
- Opioid-use Disorder, Opioid Dependence, Opiate Dependence
- Trial name
- NCT03769025
- Testing
- Suboxone Remote Observed Dosing, Suboxone Attention Control
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Pennsylvania
Opioid-Related Disorders, Opiate Dependence
Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence
The purpose of the study was to assess the efficacy of induction treatment with buprenorphine/naloxone (BNX) sublingual tablet s compared with induction treatment with buprenorphine only.
- Trial name
- NCT01848054
- Testing
- Buprenorphine/naloxone sublingual tablets, Buprenorphine
- Where
- 14 sites in United States
- Volunteers
- 313 people
- Sponsor
- Orexo AB
Opioid Dependence, Opioid Withdrawal
Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals
This study involves inducting treatment seeking opioid dependent participants onto buprenorphine. Once the participant reaches a stable dose they will receive either placebo or gabapentin to determine if gabapentin helps ease…
- Conditions
- Opioid Dependence, Opioid Withdrawal, Opioid Detoxification
- Trial name
- Detox (NCT01262092)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Arkansas
Opioid-Related Disorders, Opioid Dependence
An Innovative Intervention for OUD Treatment
The Bridge Device (BD) is a neuromodulator medical device that has been cleared by the FDA for Opioid Use Disorder (OUD) treatment.
- Conditions
- Opioid-Related Disorders, Opioid Dependence, Opioid Addiction, Opioid Withdrawal
- Trial name
- Bridge (NCT04325659)
- Testing
- Bridge Device, Lofexidine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Opioid-use Disorder
A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders
This study is an open--label randomized outpatient trial to evaluate feasibility and efficacy of rapid buprenorphine (BUP) discontinuation followed by brief course of treatment with long--acting naltrexone (XR--NTX) and to…
- Trial name
- NCT03232346
- Testing
- Vivitrol, Buprenorphine
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Opioid Dependence, Heroin Dependence
Memantine as a Supplement to Naltrexone in Treating Heroin Dependence
Prospective participants will undergo a screening process at the clinic to determine eligibility. After screening, eligible patients will complete an 8-day inpatient detoxification, followed by a 12-week outpatient phase.
- Trial name
- NAMHS (NCT00476242)
- Testing
- Vivitrol, memantine
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- New York State Psychiatric Institute
Neonatal Abstinence Syndrome
Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants
Thousands of critically ill infants (and children) are exposed to opioids and benzodiazepines to achieve sedation and analgesia as part of routine care in neonatal and pediatric intensive care units.
- Trial name
- NCT01360450
- Testing
- Clonidine HCL, saline
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Johns Hopkins University
Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome
HIV, Buprenorphine, and the Criminal Justice System
The aims of STRIDE were changed as of July, 2014. The revised project, called STRIDE2, has a longitudinal, non-randomized, observational study design.
- Conditions
- Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction, Drug Dependence
- Trial name
- STRIDE (NCT01550341)
- Testing
- Buprenorphine/naloxone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Opioid-Induced Hyperalgesia
Hyperalgesia in Methadone-Maintained Patients: Can it be Treated?
Utilizing a double-blind, placebo-controlled design, the proposed work will evaluate the ability of an adjuvant anticonvulsant analgesic to diminish or reverse the opioid-induced hyperalgesia complicating the pain states suffered…
- Trial name
- NCT01210079
- Testing
- Gabapentin;
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, Los Angeles
Heroin Addiction
Buprenorphine for Prisoners
This five-year study examines the effectiveness of buprenorphine treatment provided to previously-addicted inmates(N=320; 160 males, 160 females) initiated in prison and continued in the community.
- Trial name
- NCT00574067
- Testing
- Buprenorphine +OTP, Buprenorphine +CHC, Counseling +OTP
- Where
- 2 sites in United States
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- Friends Research Institute, Inc.
Opioid Dependence
Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults
The purpose of this study is to examine the effect of memantine and buprenorphine on opioid abusing behavior, to determine the effect of memantine and buprenorphine on early relapse and to evaluate the tolerability of memantine…
- Trial name
- NCT01052662
- Testing
- Memantine
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- University of Massachusetts, Worcester
Opiate-related Disorders, Opiate Dependence
Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)
This study is designed to determine if opioid dependent subjects who are already receiving Subutex® prefer the Suboxone® tablet over the Subutex® tablet after switching from Subutex® to Suboxone®.
- Conditions
- Opiate-related Disorders, Opiate Dependence, Drug Abuse
- Trial name
- NCT00684073
- Testing
- buprenorphine, buprenorphine/naloxone
- Volunteers
- 60 people
- Sponsor
- Indivior Inc.
Opioid Use Disorders
Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence
Phase III, randomized, double-blind, double-dummy, active-controlled, parallel group multi-center trial, designed to evaluate the non-inferiority of CAM2038 compared to an existing standard of care (SL BPN/NX) in initiation and…
- Trial name
- NCT02651584
- Testing
- CAM2038 SC injection, SL BPN/NX tabs
- Where
- 36 sites in United States
- Volunteers
- 428 people
- Sponsor
- Braeburn Pharmaceuticals
Opiate Dependence
Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone
This study is a collaboration between the University of Pennsylvania, the Philadelphia Prison System, and the North East Treatment Center (NETSteps).
- Trial name
- OAPXRNTX (NCT02617628)
- Testing
- extended release naltrexone
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Opioid Dependence
A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration
This phase 4 study will evaluate the feasibility of initiating subjects on VIVITROL in prison and continuing VIVITROL upon release into the community.
- Trial name
- NCT01453374
- Testing
- VIVITROL 380mg
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Alkermes, Inc.
Opioid Use Disorders
mHealth to Help Pregnant and Postpartum Women in Recovery for Opioid Use Disorder
The opioid epidemic has resulted in widespread detrimental consequences among vulnerable populations in Missouri, especially among pregnant and postpartum women (PPW) with opioid use disorder (OUD).
- Trial name
- NCT06701123
- Testing
- uMAT-R mobile app with coaching component
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Washington University School of Medicine
Opiate Dependence
Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence
The purpose of this study is to evaluate a very low dose naltrexone-buprenorphine treatment to transfer opioid dependent individuals to extended release naltrexone injection (Vivitrol).
- Trial name
- BUP/NXT-VIVI (NCT01690546)
- Testing
- very low dose naltrexone, extended release naltrexone, buprenorphine/naloxone
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Paolo Mannelli